Optimal treatment for each patient differs by one’s genetic mutation.

With this discovery, anticancer therapies targeting individualized genes have emerged one after another, and the field of precision medicine is evolving from ‘disease-targeted’ to ‘gene-targeted’ prescriptions.

In particular, anticipation in the field is rising with the nearing possibility of prescribing NTRK(Neurotrophic tyrosine receptor kinase) inhibitors and the introduction of RET-targeted therapies in Korea.

◆'Rozlytrek ' and 'Vitrakvi'

Roche Korea’s 'Rozlytrek (entrectinib)’ and Bayer Korea’s ‘Vitrakvi (Larotrectinib)’ are undergoing processes to receive insurance